News Roche licenses Innovent ADC that could challenge Amgen drug Roche licenses rights to a DLL3-targeted ADC from China's Innovent, hoping to bring a competitor to Amgen's lung cancer therapy Imdelltra to market.
News MSD makes its obesity move with $2bn Hansoh deal MSD has been rumoured to be considering a takeover of Viking Therapeutics in order to get a horse in the obesity therapy race, but chose instead to back a runner from China's Hansoh Pharma.
News GSK builds neuro, cancer pipeline with trio of deals GSK has added to its R&D pipeline via partnerships with Muna Therapeutics, Rgenta Therapeutics, and Duality Biologics.
News Genmab expands its pipeline with $630m Scancell deal Genmab has licensed another anti-glycan antibody for cancer from UK biotech Scancell as it continues to expand its in-house pipeline.
News Gilead looks beyond Trodelvy with Tubulis alliance Gilead Sciences has shored up its antibody-drug conjugate pipeline by licensing a candidate from German biotech Tubulis in a deal worth up to $415m.
News Ipsen doubles up in TCEs for cancer, adding Biomunex drug Ipsen has expanded its oncology pipeline by licensing a T cell engager (TCE) therapy from Paris-based startup Biomunex for up to $610m.
News MSD buys Irish vaccines plant from WuXi for €500m MSD has expanded its presence in Ireland with an agreement to buy a vaccines manufacturing facility from WuXi Biologics in Dundalk.
Digital Sponsored The AI effect in pharma commercial strategy: From data to re... Discover how AI is transforming the pharma commercial strategy. Unlock real-time insights & actions from data. Click here for more.